CardioExchange Archive

November 14th, 2011

PALLAS Intrigue: What Role Remains for Dronedarone?

CardioExchange Editors, Staff

John Mandrola, Eric Prystowsky, and Sanjay Kaul weigh in on PALLAS and the present and future of Multaq.

---

November 14th, 2011

PALLAS: Poor Results for Dronedarone in Permanent AF

Larry Husten, PHD

After a brief announcement earlier this year that the trial had been terminated early, the full results of PALLAS  (Permanent Atrial Fibrillation Outcomes Study Using Dronedarone on Top of Standard Therapy) have now been presented at the AHA and  published simultaneously in the New England Journal of Medicine. PALLAS shows that dronedarone (Multaq, Sanofi) should not be used in patients […]

---

August 4th, 2011

Easy Come, Easy Go? ESC to Review Dronedarone’s Role in AF Guidelines

Larry Husten, PHD

Less than a year after speeding into the European Society of Cardiology’s atrial fibrillation guidelines with a class 1 recommendation, the role of dronedarone (Multaq, Sanofi) in the treatment of AF will be reconsidered. “The ESC will produce a focused update of the AF Guidelines when the full results of PALLAS have been published and regulatory authorities […]

---

July 21st, 2011

FDA and EMA Issue Updates on Dronedarone, Varenicline, and Pioglitazone

Larry Husten, PHD

The FDA has issued an update on dronedarone (Multaq, Sanofi Aventis), and the European Medicines Agency (EMA) has updated its reviews of dronedarone and 2 other drugs that also have been the subject of recent controversies: pioglitazone (Actos and other names, Takeda) and varenicline (Champix, Pfizer). The FDA and dronedarone: The FDA issued a safety communication about […]

---